[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kringle Pharma, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100648453","phase-3-additional-phase-3-study-of-kp-100it-in-subjects-with-acute-spinal-cord-injury-100648453",false,"NCT07722962","Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury","An Additional Phase 3, Multicenter Study of Intrathecal Administration of KP-100IT in Subjects With Acute Spinal Cord Injury","Inclusion Criteria:\n\n* Patients whose AIS grade is A at 72 hours (± 6 hours) after injury\n* age: 18 years to 89 years\n* MRI imaging and other tests confirm the continuity of the spinal cord\n\nExclusion Criteria:\n\n* The injury site is C1-C2 or C2-C3\n* The patient with a spinal crd compression rate of 70% or higher.\n* The patient in whom a spinal cord rupture is strongle suspected.\n* The patient cannot start rehabilitation necessary for recovery of function at an early stage.\n* External trauma or concurrent organ injury.\n* High dose steroid therapy administered for the treatment of spinal cord injury\n* History or concurrent presence of malignant tumor.\n* It is inappropriate for the subject to be included in the study, in the opinion of the investigator.","ALL","18 Years","89 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg\u002Fbody by intrathecal administration once per week for a total of 5 doses and will be followed for approximately 24 weeks after the first dose.",[27],"Acute Spinal Cord Injury (SCI)",[29,30,31],"KP-100IT","Hepatocyte growth factor","Intrathecal administration","NOT_YET_RECRUITING","2026-07-20",{"date":35,"type":36},"2026-07-23","ACTUAL",{"date":38,"type":21},"2026-07-31",{"date":40,"type":21},"2028-12-31",{"name":42,"class":43},"Kringle Pharma, Inc.","INDUSTRY",3,""]